Literature DB >> 1846329

Asbestos fibres inhibit the in vitro activity of lymphokine-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma.

L S Manning1, M R Davis, B W Robinson.   

Abstract

Asbestos exposure is associated with an increased incidence of several malignancies, including malignant mesothelioma (MM). This study evaluates the relationship between asbestos exposure and the in vitro generation and function of LAK cells, an immune effector cell population with powerful lytic activity against MM cells. Both serpentine (chrysotile) and amphibole (amosite and crocidolite) forms of asbestos fibres suppress LAK cell generation, viability (by 5-11%, P less than 0.02) and cell recovery (by 13-15%, P less than 0.02). However, the LAK cells generated in the presence of the amphiboles were as effective as unexposed cells in lysing both standard tumour cell targets (K562, 56.4% lysis versus 61.5%, respectively, P greater than 0.5; NS; Daudi, 60.5% lysis versus 64.5% P greater than 0.5; NS), and MM tumour cell targets (mean of three MM cell lines 48.3% versus 46.3%, P greater than 0.5; NS), whereas the function of LAK cells generated in the presence of chrysotile was significantly reduced against three out of the five tumour cell targets tested (P less than 0.03). In the presence of asbestos fibres, LAK cell function was reduced against all five tumour cell targets (P less than 0.01), irrespective of whether the cell donors were healthy individuals or patients with MM. NK cell activity was also suppressed (P less than 0.01). The serpentine form of asbestos, chrysotile, was significantly more suppressive of both effector cell functions than either of the amphiboles (P less than 0.01). These findings suggest that asbestos exposure may suppress the function and in some instances the generation of immune effector cell mechanisms, thereby increasing the risk of disease and malignancy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846329      PMCID: PMC1535470          DOI: 10.1111/j.1365-2249.1991.tb05593.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Topographic distribution of asbestos fibres in human lung in relation to occupational and non-occupational exposure.

Authors:  P Sebastien; A Fondimare; J Bignon; G Monchaux; J Desbordes; G Bonnaud
Journal:  Inhaled Part       Date:  1975-09

2.  Immunological studies of patients with asbestosis. I. Studies of cell-mediated immunity.

Authors:  E Kagan; A Solomon; J C Cochrane; E I Beissner; J Gluckman; P H Rocks; I Webster
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

Review 3.  Current pathogenetic concepts of diffuse malignant mesothelioma.

Authors:  J E Craighead
Journal:  Hum Pathol       Date:  1987-06       Impact factor: 3.466

4.  Effects of in vitro asbestos exposure on natural killer and antibody-dependent cellular cytotoxicity.

Authors:  R G Barbers; J Oishi
Journal:  Environ Res       Date:  1987-06       Impact factor: 6.498

5.  Asbestos-associated chromosomal changes in human mesothelial cells.

Authors:  J F Lechner; T Tokiwa; M LaVeck; W F Benedict; S Banks-Schlegel; H Yeager; A Banerjee; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

6.  Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.

Authors:  L S Manning; R V Bowman; S B Darby; B W Robinson
Journal:  Am Rev Respir Dis       Date:  1989-06

7.  Impairments in functional subsets of T-suppressor (CD8) lymphocytes, monocytes, and natural killer cells among asbestos-exposed workers.

Authors:  P H Tsang; F N Chu; A Fischbein; J G Bekesi
Journal:  Clin Immunol Immunopathol       Date:  1988-06

8.  Effects of asbestos and beryllium on release of alveolar macrophage enzymes.

Authors:  K Y Kang; D Bice; R D'Amato; M Ziskind; J Salvaggio
Journal:  Arch Environ Health       Date:  1979 May-Jun

Review 9.  NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

Authors:  S A Rosenberg; M T Lotze; J J Mulé
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

10.  Pleural mesothelial cells stimulated by asbestos release chemotactic activity for neutrophils in vitro.

Authors:  V B Antony; C L Owen; K J Hadley
Journal:  Am Rev Respir Dis       Date:  1989-01
View more
  5 in total

1.  Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases.

Authors:  M Tani; H Tanimura; H Yamaue; S Mizobata; M Yamamoto; M Iwahashi; K Ura; Y Nagai; T Tsunoda; H Wakasaki; K Nanjo; K Fujino; S Yukawa
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 2.  Current therapy for malignant mesothelioma.

Authors:  W Roy Smythe
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.945

Review 3.  Nonpulmonary outcomes of asbestos exposure.

Authors:  Melisa Bunderson-Schelvan; Jean C Pfau; Robert Crouch; Andrij Holian
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

4.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

5.  One-year follow-up of the phagocytic activity of leukocytes after exposure of rats to asbestos and basalt fibers.

Authors:  M Hurbánková
Journal:  Environ Health Perspect       Date:  1994-10       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.